Summary
36 / 100 · Bulios Score
What speaks for it
- Revenue grew by 19% a year over the last 3 years.
- Analysts expect revenue to grow by 25% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 17.3 years of operating profit.
- The share price is above the Bulios Fair Price.
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (CAD)
Diluted EPS (CAD)
- Analyst estimate
Revenue grew by 48% a year over 5 years. Over the last 3 years it grew by 19% a year. For the next fiscal year analysts expect revenue to grow by 25%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $33.2M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 7.8 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $2.7 is 3.4% above today's price. 75% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2022By product
The company reports no revenue by product.
By region
- Canada 83%
- USA 17%
Canada brings in 83% of revenue.
Segments in detail